This is a very incredible honor as only three of nine hundred faculty members were accepted.
Please join us in congratulating Daniel Bowles, MD and Brandon McMahon, MD on their new roles within the Hematology/Oncology Fellowship Program.
The University of Colorado's Division of Medical Oncology was strongly represented by our talented and deticated APPs at this year's JADPRO Live at APSHO in Houson.
When the group used TAK-228 to block mTOR signaling, instead of becoming senescent, triple-negative breast cancer cells died.
Studies show regular exercise can reduce the risk of breast cancer. Orangetheory Fitness & UCH are teaming to help people fight the disease.
We wish the best for Leila in her future projects and will miss her very much as she has been an incredible asset to this Division.
We would like to thank Barbara Helfrich on her 25 years of service with the University and congratulate her on her recent retirement. She will be missed.
Late-Breaking Abstract presentations of phase III trial data give exciting new insights into the future of treatment.
Congratulations to Antonio Jimeno and his lab!
In recent years, dramatic anti-cancer responses have become possible for some patients with advanced NSCLC with targeted therapies used against specific mutations.
A college baseball coach, battling a rare form of liver cancer, got some encouragement Tuesday from the pros.
Adding to the challenge is that identifying a MET fusion gene requires not only testing for MET, but testing in a very specific way.
“We’ve done it. We’ve finally done it. We’ve finally shown this is important,” Lyons says.
Carver, a 2-year-old Coloradan battling cancer, is currently in remission thanks to an experimental drug.
In short, the answer is yes – a deeper initial response leads to a longer overall response.
The endowed chair in esophageal cancer was made possible by the Rady’s gift of $3.15 million.
Lieu will lead CU Cancer Center’s efforts in further developing an Investigator-Initiated Trials Committee.
Congratulations to Dr. Lyons and her team!
It is also the role of NCCN Guidelines panels to interpret the results of clinical trials through the lens of their own experience and expertise.
"Epacadostat plus nivolumab was active in phase 2 melanoma and squamous cell carcinoma of the head and neck cohorts," said study coauthor Karl D. Lewis, M.D
Seventeen patients were enrolled in the study with a median age of 75 years and 14 with metastatic disease.
One of our long-term patients is in college now and is studying to go on to nursing school as a result of her experience,” Gore says.
The primary endpoint of the study was progression free survival (PFS), the time that a patient can live with a cancer without it getting worse.
Overall survival was median 5.9 months for the two-drug combination and 9.6 months with the addition of vemurafenib.
D. Ross Camidge, MD, PhD, has been instrumental in the development and testing of next-generation ALK-inhibitors against ALK-positive non-small cell lung cancer.
Although she researched bacteria and plant genomics, she wanted to get back into the cancer field after earning her doctorate.
Barb Helfrich and Isabel Schlaepfer: honorees of celebrating 25 years of service in CU medicine.
Dr. Hirsch has been instrumental in prioritizing and elevating mesothelioma research within IASLC and its membership.
"I never thought it would be me with colon cancer at 25-years-old," said Brant. "They just thought it might be colitis or irritable bowel syndrome."
The DigniCap was recently approved for use by the FDA. The cap connects to a machine that monitors the cap’s temperature.
Six center: 351 patient study suggests best order of treatment for brain metastases in EGFR lung cancer
"It is an umbrella grant that provides infrastructure, at least partial infrastructure, for supportive clinical trials," Dr. Anthony Elias said.
CU researchers explore how improving fitness and body camposition can impact life for cancer survivors.
Jerry Williams has no big plans for his future. And he likes it that way.
“Based on what we’re learning, the microbiome has astounding potential. We see opportunity and we just need to drive it ahead.”
Clinical trials have proven the power of immunotherapies targeting PD-L1 or PD-1 in a range of cancers
The Broncos singled him out, bringing him a signed football and four tickets to the Broncos-Raiders game on New Year’s Day.
Ross Camidge MD, has joined a short list of lung cancer experts honored with the “A Breath Away from the Cure” Award.
“It is important to spread the message that lung cancer affects everyone: young and old, rich and poor, smoker and non-smoker."
Ellen March credits her breast cancer diagnosis to an unlikely source – her infant twins.
“This money can really help jumpstart early stage investigator’s careers and thereby ensure the future of cancer research,” says Richer.
Cancer does not discriminate. Sometimes it chooses the young and the healthy, and while cancer may take a life, it can never take away the gift that some choose to leave behind.
It’s a success in new medicine that medical experts hope will continue in the ongoing fight against not just ovarian cancer, but all forms of cancer.
“SOX2 and aldehyde inhibitors are now under exploration, and we’ve also done trials of early PI3K inhibitors here at CU Cancer Center,” Jimeno says.
The head of the Division of Medical Oncology at the University of Colorado to lead a new cancer-research center at the University of Texas.
Kelly Schneiderman expresses gratitude for the care UCH provided his father by donating a much-needed SUV.
“It is a good cautionary tale to say, ‘Question your assumptions and do as many appropriate controls as you can to make sure you really have what you think you have,’”
Tess and her husband, Joe, were excited to be having a sibling for 3-year-old, Zoe. But eight weeks into her pregnancy, the doctor found a lump in Carruth’s right breast.
He was given no chance to survive his cancer, and doctors were talking about putting him in hospice care.
Clinical cancer trials saved Elisa’s life, allowing her to become a mother, and then later, enabling her to raise her son.
“It feels like they are giving the ultimate gift,” Camidge said. “They are saying, ‘I trust you and respect you. This is my endowment to you. Do something great with it.’”
Denver City Councilman and former CU Buffaloes linebacker Albus Brooks was literally running full-tilt into summer when a diagnosis stopped him in his tracks.
The immediate danger, say Serkova and Eckhardt, is that patients are missing out on successful treatments because current measures make them seem unsuccessful.
The University of Colorado Cancer Center has enrolled 500 patients in a unique research collaboration to advance our understanding of cancer and how to treat it.
The core of this mission involves sharing information; giving researchers & research institutions datasets to compare genomics & clinical therapies.
"We try to provide a pathway that makes joining the campus community as seamless as possible"
Teams of specialists have “substantial impact” on changes in diagnosis, management of gastrointestinal cancer patients.
HiPub looks through all this text and tries to recognize what is being called genes, proteins, drugs and diseases.
The STAR Program, which integrates clinical treatment and rehabilitation services for cancer patients, will soon to debut at UCHealth hospitals in metro Denver and Colorado Springs.
Pilot programs, be they on television or in cancer centers, come and go. A precious few, though, find a devoted audience and become a core offering.
Jeb and his extended family are cautiously optimistic after an ordeal that included four one-week-long cycles of chemotherapy at University of Colorado Hospital.
The pain in her lower-right pelvis was attributed to an ovarian cyst, a painful condition but not one to be too concerned about.
A multidisciplinary approach to gastrointestinal oncology care may have a substantial impact on how cancer is diagnosed.
But it’s more than simply meeting a challenge that motivates Hancock. He likes to be where the action is. That’s why he first chose to go into oncology.
“The focus has shifted from killing the tumor to also treating the patient as an individual who has survived cancer in the context of their family and community,”
Why natural selection and not just mutations causes cancer... And how CU doctors are harnessing evolution to stop it.
As colorectal cancer rate falls, diagnosis of late-stage cancer in young patients is up
While increased screening continues to drive down overall colorectal cancer rates, the rate of colorectal cancer in patients under age 50 is increasing...
CU Cancer Center’s Paul Bunn, Jr., MD, FASCO, earns ASCO David A. Karnofsky Memorial Award
If you hate to exercise, you may benefit from a type of talk therapy that helps people accept negative feelings and uncomfortable sensations.
Among the newcomers are five providers from Front Range Cancer Specialists, which joined UCHealth Cancer Care and Hematology on April 1.
She went through rounds of chemotherapy and radiation, but the cancer kept spreading.
Metabiomics will invest $23.5 million to develop a non-invasive test for earlier and more accurate detection of colon polyps and colorectal cancer (CRC).....
North Mississippi Health Services is pleased to announce Tom Purcell, M.D., M.B.A., is returning to his hometown...
Updated results on the ongoing phase 1b clinical trial of anti-PDL1 immunotherapy atezolizumab in advanced stage colorectal cancer patients.
A University of Colorado Cancer Center study presented at the American Association for Cancer Research Annual Meeting 2016 pinpoints ways that cancer cells evolve to resist the drug LOXO-101.
These articles originally were published in a 48-page special section of the Denver Business Journal, March 25-31, 2016.
A University of Colorado Cancer study published today in the Journal of the American Medical Informatics Association describes a new tool that interprets the raw data of whole...
A University of Colorado Cancer Center study published today in the Journal of Clinical Oncology used 143,032...
Tears stream from behind Nichol Miller’s glasses as she studies the latest CAT scan of her torso. Where just four months ago tumors covered both lungs....
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
Groundbreaking research presented by international leaders in lung cancer highlighted the benefits of focusing on the prevention of lung cancer.
The University of Colorado announced the establishment of the Pia and Fred R. Hirsch Endowed Chair in Lung Cancer Research.
Associate Professor Virginia “Ginger” Borges, MD, has been appointed the first Robert F. and Patricia Young Connor Chair.
Its Lung Cancer Awareness month, BUT you wouldn’t really know it would you?
Study shows TAK-733 may be second-generation alternative for BRAF-mutant melanoma.
Event raises awareness and funding for research on pancreatic cancer.
A team at the University of Colorado Cancer Center is saying “no” to shaving for the month to raise awareness for men’s health.
NEJM: Crizotinib Effective in Phase 1 Trial Against ROS1 Lung Cancer
Drs. Elias and Lam accepted the 2014 FRCC ice bucket challenge from Dr. Heide Ford!
Colorado cancer researchers are making major strides in personalized treatment for the deadliest of cancers -- lung cancer.
A test that works much like a Breathalyzer may be able to detect lung cancer in its early stages and could pave the way for more effective treatment of the deadly disease.
It’s known best as a long-term treatment for breast-cancer survivors. But it’s also a preventive therapy: once-a-day pills proven to lower the risk of getting breast cancer in the first place.
University of Colorado Cancer Center among the best in cancer care. Services for cancer survivors are ranked 15th in the country up from 23rd in 2013.
Dr. Weekes accepted into ASCO Leadership Development Program
Dr. Bunn earns 2014 “Giants of Cancer Care” award!
The University of Colorado Cancer Center and The University of Texas MD Anderson Cancer Center were recently awarded a competitive $4.25 million, grant by the National Cancer Institute.
Cancer researchers and pharmaceutical companies alike have long recognized a weakness in many of their trials: broadly speaking, minorities have been underrepresented.
We would like to congratulate Gail Eckhardt, MD on being awarded a UM1 from NCI!
Dr. Doebele awarded CU-AMC Inventor of the Year and had the most highly-cited clinical cancer research articles published in 2012.